Trials / Completed
CompletedNCT01617954
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 820 (actual)
- Sponsor
- Agendia · Industry
- Sex
- Female
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.
Detailed description
The frequency of chemotherapy + endocrine versus endocrine alone decisions in Oncotype DX intermediate score patients will be calculated before and after receiving the MammaPrint result.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | MammaPrint | All subjects |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2012-06-13
- Last updated
- 2016-01-29
Locations
53 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01617954. Inclusion in this directory is not an endorsement.